Differential activation of the μ-opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model

British Journal of Pharmacology

Volumn 168, Issue 2, 2013, Pages 375-388

  Nakamura, Atsushi ^a   Hasegawa, Minoru ^a   Minami, Kazuhisa ^a   Kanbara, Tomoe ^a   Tomii, Takako ^a   Nishiyori, Atsushi ^a   Narita, Minoru ^b   Suzuki, Tsutomu ^b   Kato, Akira ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

opioid receptor; analgesic effect; bone cancer pain; G protein; morphine; oxycodone

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; MORPHINE; MU OPIATE RECEPTOR; OXYCODONE;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BONE CANCER; CANCER PAIN; CELL MEMBRANE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; ENZYME ACTIVATION; FEMUR; MOUSE; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; TAIL FLICK TEST;

ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; BONE NEOPLASMS; BRAIN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MICE; MICE, INBRED C3H; MORPHINE; OXYCODONE; PAIN; RECEPTORS, OPIOID, MU; SPINAL CORD;

EID: 84871576242     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02139.x     Document Type: Article

References (47)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Basbaum AI, Fields HL, (1984). Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 7: 309-338.
3. Basbaum AI, Jessell TM, (2000). The perception of pain. In:, Kandel ER, Schwartz JH, Jessell TM, (eds). Principles of Neural Science. McGraw-Hill: New York, pp. 472-491.
4. Becker R, Jakob D, Uhle EI, Riegel T, Bertalanffy H, (2000). The significance of intrathecal opioid therapy for the treatment of neuropathic cancer pain conditions. Stereotact Funct Neurosug 75: 16-26.
5. Bercovitch M, Adunsky A, (2006). High dose controlled-release oxycodone in hospice care. J Pain Palliat Care Pharmacother 20: 33-39.
6. Birukova AA, Adyshev D, Gorshkov B, Bokoch GM, Birukov KG, Verin AD, (2006). GEF-H1 is involved in agonist-induced human pulmonary endothelial barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 390: L540-L548.
7. Brunton J, Charpak S, (1998). mu-Opioid peptides inhibit thalamic neurons. J Neurosci 18: 1671-1678.
8. Chen Y, Mestek A, Liu J, Hurley JA, Yu L, (1993). Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol 44: 8-12.
9. Cherny N, (2000). New strategies in opioid therapy for cancer pain. J Oncol Manage 9: 8-15.
10. Cohen SR, Melzack R, (1985). Morphine injected into the habenula and dorsal posteromedial thalamus produces analgesia in the formalin test. Brain Res 359: 131-139.
11. Cordeaux Y, Briddon SJ, Megson AE, Mcdonnell J, Dickenson J, (2000). Influence of receptor number on functional responses elicited by agonists acting at the human adenosine A1 receptor: evidence for signalling pathway-dependent changes in agonist potency and relative intrinsic activity. Mol Pharmacol 58: 1075-2000.
12. Cox BM, Weinstock M, (1964). Quantitative studies of the antagonism by nalorphine of some of the actions of morphine-like analgesia drugs. Br J Pharmacol 22: 289-300.
13. Gimbel JS, Richards P, Portenoy RK, (2003). Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 60: 927-934.
14. Heiskanen T, Kalso E, (1997). Controlled-release oxycodone and morphine in cancer related pain. Pain 73: 37-45.
15. Honore P, Lugar NM, Sabino MAC, Schwei MJ, Rogers SD, Mash DB, et al,. (2000). Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-induced neurochemical reorganization of the spinal cord. Nat Med 6: 521-528.
16. Kalso E, (2005). Oxycodone. J Pain Symptom Manage 29: S47-S56.
17. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010) NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
18. Komiya S, Zenmyo M, Inoue A, (1999). Bone tumors in the pelvis presenting growth during pregnancy. Arch Orthop Trauma Surg 119: 22-29.
19. Koshy RC, Rhodes D, Devi A, Grossman SA, (1998). Cancer pain management in developing countries: a mosaic of complex issues resulting in inadequate analgesia. Support Care Cancer 6: 430-437.
20. Lazareno S, (1997). Measurement of agonist-stimulated [35S]GTPγS binding to cell membranes. Methods Mol Biol 83: 107-116.
21. Lemberg KK, Kontinen VK, Siiskonen AO, Viljakka KM, Yli-Kauhaluoma JT, Korpi ER, et al,. (2006). Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats. Anesthesiology 105: 801-812.
22. Levy MH, (1996). Pharmacologic treatment of cancer pain. N Engl J Med 10: 1124-1132.
23. Luger NM, Sabino MA, Schwei MJ, Mach DB, Pomonis JD, Keyser CP, et al,. (2002). Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs inflammatory pain. Pain 99: 397-406.
24. McDonald J, Barnes TA, Okawa H, Williams J, Calo G, Rowbotham DJ, et al,. (2003). Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone-inducuble mammalian expression system. Br J Pharmacol 140: 61-70.
25. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
26. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE, (1976). The effects of morphine and nalorphine-like drugs in the nondependent and morphine dependent chronic spinal dog. J Pharmacol Exp Ther 197: 517-532.
27. Mercadante S, Arcuri E, (1998). Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 24: 425-432.
28. Min BH, Augustin LB, Felsheim RF, Fuchs JA, Loh HH, (1994). Genomic structure and analysis of promoter sequence of a mouse μ opioid receptor gene. Proc Natl Acad Sci U S A 91: 9081-9085.
29. Minami K, Hasegawa M, Ito H, Nakamura A, Tomii T, Matsumoto M, et al,. (2009). Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models. J Pharmacol Sci 111: 60-72.
30. Narita M, Mizoguchi H, Narita M, Sora I, Uhl GR, Tseng LF, (1999). Absence of G-protein activation by μ-opioid receptor knockout mice. Br J Pharmacol 123: 451-456.
31. 5] enkephalin. J Neurosci 21: 3715-3720.
32. Narita M, Nakamura A, Ozaki M, Imai S, Miyoshi K, Suzuki M, et al,. (2008). Comparative pharmacological profiles of morphine and oxycodone under a neuropathic pain-like state in mice: evidence for less sensitivity to morphine. Neuropsychopharmacology 33: 1097-1112.
33. Nielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, Smith MT, (2007). Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 132: 289-300.
34. Pandit-Taskar N, Batraki M, Divgi CR, (2004). Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 45: 1358-1365.
35. Paxinos G, Franklin KBJ, (2008). The Mouse Brain in Stereotaxic Coordinates. Academic Press: New York, NY.
36. Peckham EM, Traynor JR, (2006). Comparison of the antinociceptive responses to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther 316: 1195-1201.
37. Pert CB, Snyder SH, (1973). Opiate receptor: demonstration in nervous tissue. Science 179: 1011-1014.
38. Portenoy RK, Payne D, Jacobsen P, (1999). Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81: 129-134.
39. Ross FB, Smith MT, (1997). The intrinsic antinociceptive effects of oxycodone appear to be κ-opioid receptor mediated. Pain 73: 151-157.
40. Silvestri B, Bandieri E, Del Prete S, Ianniello GP, Micheletto G, Dambrosio M, et al,. (2008). Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study. Clin Drug Investig 28: 399-407.
41. Veatch RM, Adler TK, Way EL, (1964). The importance of steric configuration in certain morphine-mimetics of synthetic analgetics. J Pharmacol Exp Ther 145: 11-19.
42. Watson CP, Babul N, (1998). Efficacy of oxycodone in neuropathic pain. A randomized trial in post herpetic neuralgia. Neurology 50: 1837-1841.
43. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J, (2003). Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 105: 71-78.
44. Yamamoto J, Kawamata T, Niiyama Y, Omote K, Namiki A, (2008). Down-regulation of mu opioid receptor expression within distinct subpopulations of dorsal root ganglion neurons in a murine model of bone cancer pain. Neuroscience 6: 843-853.
45. Zangen A, Herzberg U, Vogel Z, Yadid G, (1998). Nociceptive stimulus induced release of endogenous beta-endorphin in the rat brain. Neuroscience 85: 659-662.
46. Zhao C, Chen L, Tao YX, Tall JM, Borzan J, RingKamp M, et al,. (2007). Lumbar sympathectomy attenuates cold allodynia but not mechanical allodynia and hyperalgesia in rats with spared nerve injury. J Pain 8: 931-937.
47. Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, et al,. (2001). Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 293: 311-315.